HER2
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
HER2
May 11, 2024, 11:23 |
Insight
Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, Co-Founder and CEO of FiBioMed, shared a post by Paolo Tarantino on X,…
May 2, 2024, 15:20 |
Blog
Paolo Tarantino: Impressive to think at the journey of ADCs over the last five years
Paolo Tarantino shared on LinkedIn: "Impressive to think at the journey of ADCs over the last…
May 1, 2024, 12:05 |
Blog
Paolo Tarantino: Refresher for the current and upcoming definitions of HER2 in breast oncology
Paolo Tarantino shared on X/Twitter: "Refresher for the current and upcoming definitions of HER2 in breast…
Apr 28, 2024, 05:14 |
Insight
Aleix Prat: Our new article about attitudes towards HER2DX in Spain
Aleix Prat, Director of the Cancer Institute at Hospital Clinic of Barcelona, shared on X/Twitter:…
Apr 26, 2024, 17:44 |
Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 21, 2024, 11:35 |
Insight
Samuel Kareff: Our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors
Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, shared…
Apr 20, 2024, 20:17 |
Insight
Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Tumor-infiltrating lymphocytes (TILs): not…
Apr 12, 2024, 05:16 |
Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Apr 11, 2024, 08:13 |
Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Apr 8, 2024, 15:41 |
Drugs
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…
1
2
3
All:
28
Posts:
1 - 10
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Neuroendocrine tumors - newly updated AJCC guidelines
5 min Sarcoma Talk with Shushan Hovsepyan and Andrea Ferrari
Facebook
RSS Feed
Twitter
Linkedin
Youtube